Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxycarbamide in children with Sickle Cell Disease
NCT06578507Phase 2Recruiting
- Sponsor
- Theravia
- Start
- Jan 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of hydroxyurea in sickle cell disease (SCD), sponsored by Theravia. Primary endpoints: Area Under the Curve at 12 months, Time to Maximum Concentration at 12 months and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06578507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578507.